A novel predictive marker for placental abruption with composite adverse outcomes: creatinine–fibrinogen ratio
Archives of Gynecology and Obstetrics · 25.01.2024 · 310 (1) · 353-358
DOI: 10.1007/s00404-023-07355-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 25.01.2024. Verfasst von Osman Onur Ozkavak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Perinatology, Ankara Bilkent City Hospital, Cankaya, 06800, Ankara, Turkey. onurozkavakdr@gmail.com. Hauptthemen laut MEDLINE: Abruptio Placentae, Biomarkers, Creatinine, Fibrinogen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To develop a new cost-effective marker named creatinine-fibrinogen ratio (CFR) for the prediction of composite adverse outcomes (CAO) in placental abruption cases. METHODS: A total of 109 placental abruption patients (30 with adverse outcomes, 79 without adverse outcomes) were enrolled in this retrospective cohort study. Patients with at least one of the features listed below were included in the abruption with CAO group: requirement of blood product transfusion (erythrocyte suspension, fresh frozen plasma, pooled thrombocyte, thrombocyte apheresis), development of acute kidney injury or disseminated intravascular coagulation, and need for intensive care unit. Laboratory parameters and CFR values at admission to the hospital were compared between the two groups. RESULTS: Higher creatinine and lower fibrinogen levels were found in the CAO group (p = 0.007 and p < 0.001 respectively). The CFR value of the CAO group was significantly higher (p < 0.001). In the ROC curve analysis performed to investigate the value of CFR in CAO prediction, the area under the curve (AUC) was calculated as 0,802 (95% CI 0.709-0.895, 77% sensitivity, 65% specificity). CONCLUSION: CFR seems to be a practical marker for the prediction of CAOs in pregnant women with ablatio placenta.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Perinatology, Ankara Bilkent City Hospital, Cankaya, 06800, Ankara, Turkey. onurozkavakdr@gmail.com.
- Department of Perinatology, Ankara Bilkent City Hospital, Cankaya, 06800, Ankara, Turkey.
- Department of Obstetrics and Gynaecology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
- Department of Obstetrics and Gynaecology, Ankara Bilkent City Hospital, Ankara, Turkey.
ORCID-Profile: Osman Onur Ozkavak, Atakan Tanacan, Murat Haksever, Refaettin Sahin, Duygu Tugrul Ersak, Eda Iskefiyeli, Dilek Sahin
Zitieren
APA
Ozkavak, O. O., Tanacan, A., Haksever, M., Sahin, R., Ersak, D. T., Iskefiyeli, E., & Sahin, D. (2024). A novel predictive marker for placental abruption with composite adverse outcomes: creatinine–fibrinogen ratio. Archives of Gynecology and Obstetrics, 310(1), 353-358. https://doi.org/10.1007/s00404-023-07355-4
Vancouver
Ozkavak OO, Tanacan A, Haksever M, Sahin R, Ersak DT, Iskefiyeli E, et al. A novel predictive marker for placental abruption with composite adverse outcomes: creatinine–fibrinogen ratio. Archives of Gynecology and Obstetrics. 2024;310(1):353-358. doi:10.1007/s00404-023-07355-4
BibTeX
@article{Ozkavak2024,
author = {Ozkavak, Osman Onur and Tanacan, Atakan and Haksever, Murat and Sahin, Refaettin and Ersak, Duygu Tugrul and Iskefiyeli, Eda and Sahin, Dilek},
title = {A novel predictive marker for placental abruption with composite adverse outcomes: creatinine–fibrinogen ratio},
journal = {Archives of Gynecology and Obstetrics},
year = {2024},
volume = {310},
number = {1},
pages = {353--358},
doi = {10.1007/s00404-023-07355-4}
}
EUVIMED